WesBanco Bank’s Catalyst Pharmaceutical CPRX Stock Holding History

WesBanco Bank’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-79,000	Closed	-$1.96M	–	689
2026 Q1	$1.96M	Buy	79,000 +23,000	+41%	+$548K	0.05%	244
2025 Q4	$1.31M	Hold	56,000	–	–	0.04%	324
2025 Q3	$1.1M	Hold	56,000	–	–	0.03%	351
2025 Q2	$1.22M	Buy	56,000 +37,000	+195%	+$873K	0.04%	332
2025 Q1	$461K	Buy	+19,000	New	+$428K	0.02%	447

Other funds holding CPRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

WesBanco Bank's CPRX Position: Q2 2026 in Review

WesBanco Bank sold out of Catalyst Pharmaceutical (CPRX) in Q2 2026, closing a stake of 79,000 shares — an estimated $1.96M sold.

WesBanco Bank first reported a position in CPRX in Q1 2025 and held it in 5 quarters. The position peaked at $1.96M in Q1 2026. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

WesBanco Bank reported no remaining Catalyst Pharmaceutical position as of Q2 2026 after selling out during the quarter.
WesBanco Bank sold 79,000 Catalyst Pharmaceutical shares in Q2 2026, an estimated $1.96M.
WesBanco Bank first reported a position in Catalyst Pharmaceutical in Q1 2025 and held it in 5 quarters.
WesBanco Bank's Catalyst Pharmaceutical position peaked at $1.96M in Q1 2026.
396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on WesBanco Bank's 13F filing for Q2 2026, filed 28 Jul 2026.